{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:59:23Z","timestamp":1782471563746,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nut.2025.113024","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:52:32Z","timestamp":1763272352000},"page":"113024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluation of dietary management and monitoring practices in pharmaceutical clinical trials for inborn errors of metabolism"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6205-283X","authenticated-orcid":false,"given":"Nicole Y.","family":"McWhorter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-1405","authenticated-orcid":false,"given":"Tracy B.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Sarasua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3672-3492","authenticated-orcid":false,"given":"Christopher L.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie B.","family":"Gillingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nut.2025.113024_bib0001","series-title":"Handbook of clinical neurology","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/B978-0-444-64029-1.00022-9","article-title":"Chapter 22\u2014Inborn errors of metabolism","volume":"162","author":"Ferreira","year":"2019"},{"key":"10.1016\/j.nut.2025.113024_bib0002","series-title":"Nutrition management of inherited metabolic diseases: lessons from metabolic university","year":"2015"},{"key":"10.1016\/j.nut.2025.113024_bib0003","series-title":"Vademecum Metabolicum","author":"Zschocke","year":"2011"},{"key":"10.1016\/j.nut.2025.113024_bib0004","series-title":"Inborn errors of metabolism that use dietary management: considerations for optimizing and standardizing diet in clinical trials for drug product development","year":"2023"},{"key":"10.1016\/j.nut.2025.113024_bib0005","series-title":"Principles of nutritional assessment","author":"Gibson","year":"2005"},{"issue":"11","key":"10.1016\/j.nut.2025.113024_bib0006","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jand.2019.06.010","article-title":"Best practices for conducting and interpreting studies to validate self-report dietary assessment methods","volume":"119","author":"Kirkpatrick","year":"2019","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.nut.2025.113024_bib0007","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-1172-3-2","article-title":"Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia?","volume":"3","author":"Levrat","year":"2008","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.nut.2025.113024_bib0008","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-019-01079-z","article-title":"Phenylketonuria: current treatments and future developments","volume":"79","author":"Lichter-Konecki","year":"2019","journal-title":"Drugs"},{"issue":"7 suppl","key":"10.1016\/j.nut.2025.113024_bib0009","article-title":"Long-chain fatty acid oxidation disorders and current management strategies","volume":"26","author":"Vockley","year":"2020","journal-title":"Am J Manag Care"},{"issue":"22","key":"10.1016\/j.nut.2025.113024_bib0010","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1002\/ajmg.a.32562","article-title":"Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria","volume":"146A","author":"Lee","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"9586","key":"10.1016\/j.nut.2025.113024_bib0011","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.nut.2025.113024_bib0012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-017-0600-x","article-title":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial","volume":"12","author":"Muntau","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.nut.2025.113024_bib0013","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.nut.2025.113024_bib0014","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ymgme.2011.10.014","article-title":"START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients","volume":"105","author":"Utz","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.nut.2025.113024_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10545-007-0556-4","article-title":"Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine","volume":"30","author":"Matalon","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.nut.2025.113024_bib0016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.nut.2025.113024_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ymgme.2018.06.010","article-title":"Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria","volume":"125","author":"Zori","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nut.2025.113024_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155116","article-title":"PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study","volume":"128","author":"Bratkovic","year":"2022","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.nut.2025.113024_bib0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s42255-021-00430-7","article-title":"Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1\/2a study","volume":"3","author":"Puurunen","year":"2021","journal-title":"Nat Metab"},{"issue":"10","key":"10.1016\/j.nut.2025.113024_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s42255-023-00897-6","article-title":"Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial","volume":"5","author":"Vockley","year":"2023","journal-title":"Nat Metab"},{"issue":"2","key":"10.1016\/j.nut.2025.113024_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymgme.2014.03.012","article-title":"Use of propofol for short duration procedures in children with long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencies","volume":"112","author":"Martin","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.nut.2025.113024_bib0022","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10545-017-0085-8","article-title":"Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial","volume":"40","author":"Gillingham","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.nut.2025.113024_bib0023","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ymgme.2017.02.005","article-title":"UX007 for the treatment of long chain-fatty acid oxidation disorders: safety and efficacy in children and adults following 24weeks of treatment","volume":"120","author":"Vockley","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nut.2025.113024_bib0024","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.clnesp.2020.11.018","article-title":"Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study","volume":"41","author":"Vockley","year":"2021","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"10.1016\/j.nut.2025.113024_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12887-019-1571-y","article-title":"Evaluation of long-term effectiveness of the use of carglumic acid in patients with propionic acidemia (PA) or methylmalonic acidemia (MMA): study protocol for a randomized controlled trial","volume":"19","author":"Nashabat","year":"2019","journal-title":"BMC Pediatr"},{"issue":"1\u20132","key":"10.1016\/j.nut.2025.113024_bib0026","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2019.07.018","article-title":"Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria","volume":"128","author":"Zori","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.nut.2025.113024_bib0027","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jimd.12038","article-title":"Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD)","volume":"42","author":"Vockley","year":"2019","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.nut.2025.113024_bib0028","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ajcn\/nqz198","article-title":"Does exclusion of extreme reporters of energy intake (the \u201cGoldberg cutoffs\u201d) reliably reduce or eliminate bias in nutrition studies? Analysis with illustrative associations of energy intake with health outcomes","volume":"110","author":"Ejima","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.nut.2025.113024_bib0029","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fpsyt.2019.00561","article-title":"Psychiatric and cognitive aspects of phenylketonuria: the limitations of diet and promise of new treatments","volume":"10","author":"Ashe","year":"2019","journal-title":"Front Psychiatry"},{"issue":"9326","key":"10.1016\/j.nut.2025.113024_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(02)09334-0","article-title":"How practical are recommendations for dietary control in phenylketonuria?","volume":"360","author":"Walter","year":"2002","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.nut.2025.113024_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012927","article-title":"Dietary assessment of British police force employees: a description of diet record coding procedures and cross-sectional evaluation of dietary energy intake reporting (The Airwave Health Monitoring Study)","volume":"7","author":"Gibson","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.nut.2025.113024_bib0032","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jn\/136.2.440","article-title":"A debriefing session with a nutritionist can improve dietary assessment using food diaries","volume":"136","author":"Cantwell","year":"2006","journal-title":"J Nutr"},{"issue":"11","key":"10.1016\/j.nut.2025.113024_bib0033","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1017\/S0007114514000154","article-title":"Measuring the difference between actual and reported food intakes in the context of energy balance under laboratory conditions","volume":"111","author":"Stubbs","year":"2014","journal-title":"Br J Nutr"},{"key":"10.1016\/j.nut.2025.113024_bib0034","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.ymgme.2011.09.014","article-title":"Does a lower carbohydrate protein substitute impact on blood phenylalanine control, growth and appetite in children with PKU?","volume":"104","author":"Gokmen-Ozel","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1016\/j.nut.2025.113024_bib0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10545-010-9073-y","article-title":"The reality of dietary compliance in the management of phenylketonuria","volume":"33","author":"MacDonald","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nut.2025.113024_bib0036","series-title":"Genetic Metabolic Dietitians International (GMDI) Conference","article-title":"Dietary management outcomes during SynPheny-1, a phase 2 clinical trial of a live biotherapeutic, SYNB1618, for the management of phenylketonuria [Poster presentation]","author":"McWhorter","year":"2022"}],"container-title":["Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900725003417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900725003417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:38:46Z","timestamp":1768477126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899900725003417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"alternative-id":["S0899900725003417"],"URL":"https:\/\/doi.org\/10.1016\/j.nut.2025.113024","relation":{},"ISSN":["0899-9007"],"issn-type":[{"value":"0899-9007","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of dietary management and monitoring practices in pharmaceutical clinical trials for inborn errors of metabolism","name":"articletitle","label":"Article Title"},{"value":"Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nut.2025.113024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113024"}}